通过口和口病促进代谢干扰,以促进TNBC中的化疗
Marcus D Goncalves1, Neil M Iyengar2
1NYU Langone Health, New York, NY, USA.
Cell metabolism
|February 5, 2025
概括
禁食模仿饮食 (FMD) 显著改善了三阴性乳腺癌 (TNBC) 患者的治疗反应率. 这种饮食干预显示出承诺,副作用最小,表明未来癌症治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 代谢研究研究 代谢研究
- 免疫学 免疫学 免疫学
背景情况:
- 三阴性乳腺癌 (TNBC) 呈现高糖解,缺乏可靠的治疗反应生物标志物.
- 目前TNBC的治疗选择在疗效和预测标记上有局限性.
研究的目的:
- 为了评估一种模仿禁食饮食 (FMD) 对TNBC患者病理完整反应 (pCR) 率的影响.
- 在乳腺癌治疗的背景下评估口热的安全性和耐受性.
主要方法:
- 该研究涉及正在接受治疗的TNBC患者.
- 患者接受了类似禁食饮食 (FMD) 的干预.
- 病理完整反应 (pCR) 率与历史化疗数据进行了比较.
主要成果:
- 早餐试验显示,pCR率大幅增加,达到56.6%的口炎.
- 这一比例远远超过化学疗法的30-40%的历史平均水平.
- 口疫干预与最小的严重不良事件有关.
结论:
- 禁食模仿饮食 (FMD) 显示出显著的潜力,以提高三阴性乳腺癌的治疗疗效.
- 关节炎的代谢和免疫调节作用需要进一步研究,特别是与免疫治疗结合使用.
- 这种饮食方法提供了一种有希望的,耐受性良好的策略,用于改善TNBC的结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147


